Skip to content

    Prevest Denpro

    543363
    Healthcare·30 May 2025
    Management Summary

    Prevest Denpro delivered a resilient Q4 and FY25, with consolidated revenue growing 13.6% YoY to INR 67.09 crores and PAT increasing 12.51% to INR 18.15 crores, while maintaining strong EBITDA margins. The company is strategically expanding into digital dentistry and strengthening its US presence through Axiodent Incorporation, which saw 14% revenue growth. Despite facing a challenging market and slower growth than initially projected, management remains optimistic about future growth driven by diversification and international expansion.

    Highlights

    5
    • FY25 consolidated revenue grew 13.6% YoY to INR 67.09 crores, demonstrating steady progress.

    • EBITDA margins for FY25 remained strong at 38.98%, reflecting effective operational efficiency despite inflationary pressures.

    • PAT increased by 12.51% YoY to INR 18.15 crores, maintaining a healthy PAT margin of 27.06%.

    • Q4 FY25 showed significant momentum with revenue jumping 21.79% from Q3 to INR 19.53 crores and EBITDA margins at 39.03%.

    • Successfully launched three new cutting-edge biomaterials and made a strategic entry into digital dentistry, including 3D printers and scanners, with favorable market response.

    Concerns

    3
    • FY25 growth rate of 13.6% is lower than the 30% growth seen in previous years, attributed to challenging market conditions, foreign exchange issues, and underperformance of the Oradox product line.

    • The Oradox product line has not performed as well as anticipated, contributing only INR 50 lakhs in FY25.

    • The company has not met its prior IPO target of INR 150 crores revenue in a couple of years post-listing due to various market factors.

    What Changed1

    vs Q2 FY26

    Guidance items6 → 4 (-2)
    Key financials

    Metrics

    8

    Periods

    3

    Headline

    2
    • H2 FY25 Revenue
      ₹35.56 Cr
      YoY+12.8%
    • H2 FY25 EBITDA Margin
      39.1%

    Q4 FY25

    2
    • Revenue
      ₹19.53 Cr
      QoQ+21.8%
    • EBITDA Margin
      39.0%

    FY25

    4
    • Consolidated Revenue
      ₹67.09 Cr
      YoY+13.2%
    • EBITDA Margin
      39.0%
    • PAT
      ₹18.15 Cr
      YoY+12.5%
    • PAT Margin
      27.1%

    Capital allocation

    1
    medium confidence
    CategoryHeadline
    M&A

    Axiodent Incorporation

    acquisition · closed

    Guidance & targets

    4
    CategoryTargetPriority
    Product
    New Product Launches
    4 to 5
    High
    Revenue
    Revenue Growth
    aspire for 30%
    Low
    Revenue
    Q4 Revenue Run Rate
    maintain INR 18.5 crores
    Low
    Business Growth
    Digital Dentistry Business Growth
    reach to a better level
    Medium

    New Product Launches (FY26)

    FY26
    Current0 (for FY26 so far)
    Target4-5 new products

    Why it matters

    Indicates the company's innovation pipeline and ability to drive future growth.

    Looking ahead, we are expecting to launch at least 4 to 5 new products in the 2025-2026 fiscal year with a focus on performance, safety and clinical excellence.

    How to verify

    guidance_and_targets[category='Product'][metric='New Product Launches']

    Risks & concerns

    4
    RiskSeverity

    Challenging market environment and slower growth

    FY25 growth of 13.6% is lower than previous years due to market deflation, foreign exchange issues, and underperformance of Oradox.Management acknowledged

    medium

    Competition from multinational and Chinese companies

    The dental market is dominated by large multinational players, making it challenging for Prevest Denpro to achieve faster growth.Management acknowledged

    medium

    Oradox product line underperformance

    The Oradox product line has not performed as well as anticipated, contributing only INR 50 lakhs in FY25.Management acknowledged

    low

    Potential over-diversification

    Analyst questioned if the company's broad diversification strategy might dilute focus, but management views it as a necessary long-term move for future relevance.Analyst deflected

    low

    Q&A highlights

    7

    “See post-IPO, our growth rate was around 30%. Based on the growth rate, we estimated a revenue for the next 4 to 5 years in the range of INR 100-plus crores, around INR 120 crores and INR 125 crores. But in the last couple of years because of the market deflation, we have a very slow growth, it's around 10%. This year, we have seen a growth of 13% and moreover, the store projected was based on the new product line, which was introduced 2 years back, Oradox. Unfortunately, Oradox has not taken out so well as anticipated. And all these factors have contributed in the slowdown of growth, and we are trying our best to cope-up with the growth rate as the market situations are also improving.”

    Addresses a significant miss on prior guidance and provides reasons including market conditions and Oradox underperformance.

    asked by Gaurav

    3 min read6 chapters

    Detailed Narrative

    01

    Q4 and FY25 Financial Performance Overview

    Prevest Denpro reported a consolidated revenue of INR 67.09 crores for FY25, marking a 13.6% growth over the previous year's INR 59.29 crores. Domestic sales contributed significantly with a 13% increase, while exports grew by 10% year-on-year. The company maintained strong operational efficiency, with EBITDA margins holding steady at 38.98% for FY25, compared to 38.30% last year. Net profit after tax (PAT) for the year stood at INR 18.15 crores, reflecting a 12.51% growth and a healthy PAT margin of 27.06%. The fourth quarter was particularly strong, with revenue reaching INR 19.53 crores, a 21.79% jump from Q3, and EBITDA margins at 39.03%.

    02

    Strategic Shift to Digital Dentistry

    The company has made a bold move into digital dentistry, building on its 3D resin portfolio launched last year. This involves developing advanced 3D printers and scanners, combining in-house R&D with strategic partnerships with global suppliers. Management believes digital dentistry will be a significant growth area, with the global market projected to reach $17.9 billion by 2033, and sees this as a natural progression for the company. They aim to offer a complete end-to-end digital workflow solution for dental clinics and labs.

    03

    International Expansion and US Market Focus

    Prevest Denpro is actively expanding its international footprint, with exports growing 10% this year. A key focus is the US market, which accounts for approximately 40% of the global dental market. To enhance brand recognition and overcome the 'Made in India' perception, the company incorporated Axiodent Incorporation in the US, which saw its revenue grow by 14% this year. They are also pursuing private labeling partnerships and contract manufacturing opportunities in the US, leveraging their FDA-approved products.

    04

    R&D and New Product Development

    The R&D team is focused on innovation and translation, successfully developing three new cutting-edge biomaterials: Crysta Axis (strontium-enriched restorative material), Caries Cure SDF (silver diamine fluoride system), and Crysta LC RMGI (resin-modified glass ionomer). These products are 100% indigenously developed. The company plans to launch 4 to 5 new products in FY26, emphasizing performance, safety, and clinical excellence. Additionally, they are scaling up production of core biomaterials like hydroxyapatite and tricalcium phosphate for internal use and global commercialization to other manufacturers and medical device suppliers.

    05

    Market Challenges and Growth Outlook

    While FY25 saw 13.6% revenue growth, it was lower than the 30% growth rates seen post-IPO, attributed to market deflation, foreign exchange crises in some international markets, and the slower-than-anticipated uptake of the Oradox product line, which contributed only INR 50 lakhs. Despite these challenges, management remains optimistic, aspiring for 25-30% growth in the coming year, driven by stabilization in international markets, momentum in digital dentistry, and the US operations. They emphasize a long-term view, prioritizing consistent profitable growth over unsustainable short-term gains.

    06

    Operational Efficiency and Cost Management

    The company has focused on strengthening its fundamentals by implementing lean manufacturing principles, upgrading ERP systems, and optimizing its supply chain network. These initiatives have resulted in better asset utilization, reduced working capital, and improved production flexibility. This focus on efficiency helped maintain EBITDA margins at 38.98% for FY25 despite inflationary pressures on raw materials and logistics. Management stated that director salaries have not increased in the last 5 years and are commensurate with market standards, indicating a focus on business growth rather than cost-cutting in this area.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.